Themedical genetics of Jews have been studied to identify and prevent some rare genetic diseases that, while stillrare, are more common than average among people ofJewish descent. There are severalautosomal recessivegenetic disorders that are more common than average in ethnically Jewish populations, particularlyAshkenazi Jews, because of relatively recentpopulation bottlenecks and because ofconsanguineous marriage (marriage of second cousins or closer).[1] These two phenomena reduce genetic diversity and raise the chance that two parents will carry a mutation in the same gene and pass on both mutations to a child.
The genetics of Ashkenazi Jews have been particularly well studied because the phenomenon affects them the most. This has resulted in the discovery of many genetic disorders associated with thisethnic group.[2] The medical genetics ofSephardic Jews andMizrahi Jews are more complicated because they are genetically more diverse, and therefore no genetic disorders are more common in these groups as a whole; instead, they tend to have the genetic diseases common in their various countries of origin.[2][3]
Several organizations, such asDor Yeshorim,[4] offerscreening for Ashkenazi genetic diseases, and these programs have done much, particularly by reducing the incidence ofTay–Sachs disease.[5]
Different ethnic groups tend to have different rates of hereditary diseases, with some being more common, and some less common. Hereditary diseases, particularlyhemophilia, were recognized early inJewish history, even being described in theTalmud.[6] However, the scientific study of hereditary disease in Jewish populations was initially hindered byscientific racism, which was based onracial supremacism.[7][better source needed][8][better source needed]
However, modern studies on the genetics of particular ethnic groups have the tightly defined purpose of avoiding the birth of children with genetic diseases, or identifying people at particular risk of developing a disease in the future.[7] Consequently, some members of the Jewish community have been very supportive of modern genetic testing programs; this high level of cooperation has raised concerns that conclusions may lead to stigmatization of the Jewish community.[6]
Most populations contain hundreds ofalleles that could potentially cause disease, and most people areheterozygotes for one or tworecessive alleles that would be lethal in ahomozygote.[9] Although the overall frequency of disease-causing alleles does not vary much between populations, the practice of consanguineous marriage (marriage between second cousins or closer relatives) has been common in some Jewish communities, which produces a small increase in the number of children with congenital defects.[1]
According to Daphna Birenbaum Carmeli at theUniversity of Haifa, Jewish populations have been studied thoroughly because:[10]
The result is a form ofascertainment bias. This has sometimes created an impression that Jews are more susceptible to genetic disease than other populations. Carmeli writes, "Jews are over-represented in human genetic literature, particularly in mutation-related contexts."[10]
This set of advantages has led to Ashkenazi Jews in particular being used in many genetic studies, not just in the study of genetic diseases. For example, a series of publications on Ashkenazi centenarians established their longevity was strongly inherited and associated with lower rates of age-related diseases.[11] This "healthy aging" phenotype may be due to higher levels oftelomerase in these individuals.[12]
Because of centuries ofendogamy, today's 10 million Ashkenazi Jews descend from a population of 350 who lived about 600–800 years ago.[13][14] That population derived from both Europe and the Middle East. Some evidence shows that thepopulation bottleneck may have allowed deleteriousalleles to increase in the population bygenetic drift.[15]
This group has therefore been particularly intensively studied, and many mutations are common in Ashkenazim.[16] Of these diseases, many also occur in other Jewish groups and non-Jewish populations, although the specific mutation that causes the disease may vary among populations. For example, two mutations in theglucocerebrosidase gene each causeGaucher's disease in Ashkenazim, which is that group's most common genetic disease, but only one of these mutations is found in non-Jewish groups.[5] A few diseases are unique to this group;familial dysautonomia, for example, is almost unknown in other peoples.[5]
| Disease | Subspecialty | Mode of inheritance | Gene | Carrier frequency |
|---|---|---|---|---|
| Favism | Medical genetics | X-linked | G6PD | |
| Bloom syndrome | Medical genetics | Autosomal recessive | BLM | 1/100 |
| Breast cancer andovarian cancer | Oncology | Autosomal dominant | BRCA1 orBRCA2 | 1/100 and 1/75, respectively |
| Canavan disease | Endocrinology, neurology | Autosomal recessive | ASPA | 1/60 |
| Congenital deafness | Neurology, otorhinolaryngology, audiology | Autosomal recessive | GJB2 orGJB6 | 1/25 |
| Cystic fibrosis | Pulmonology, hepatology | Autosomal recessive | CFTR | 1/25 |
| Haemophilia C | Hematology | Autosomal recessive | F11 | 1/12 |
| Familial dysautonomia | Neurology | Autosomal recessive | IKBKAP | 1/30 |
| Familial hypercholesterolemia | Endocrinology, chemical pathology | Autosomal dominant | LDLR | 1/69 |
| Familial hyperinsulinism | Gastroenterology, endocrinology, pediatrics | Autosomal recessive | ABCC8 | 1/125–1/160 |
| Fanconi anemia C | Hematology | Autosomal recessive | FACC | 1/100 |
| Gaucher disease | Endocrinology, neurology | Autosomal recessive | GBA | 1/7–1/18 |
| Glycogen Storage Disease type 1a | Endocrinology, hematology, immunology | Autosomal recessive | G6PC | 1/71 |
| Mucolipidosis IV | Endocrinology | Autosomal recessive | MCOLN1 | 1/110 |
| Niemann–Pick (type A) | Medical genetics | Autosomal recessive | SMPD1 | 1/90 |
| Nonclassical 21 OHase deficiency | Endocrinology | Autosomal recessive | CPY21 | 1/6 |
| Parkinson's disease | Neurology | Autosomal dominant | LRRK2 | 1/42[17] |
| Tay–Sachs | Medical genetics | Autosomal recessive | HEXA | 1/25–1/30 |
| Torsion dystonia | Neurology | Autosomal dominant | DYT1 | 1/4000 |
| Usher syndrome | Ophthalmology | Autosomal recessive | PCDH15 | 1/72 |
| Warsaw breakage syndrome | Medical genetics, pediatrics | Autosomal recessive | DDX11 | 1/50[18] |
Tay–Sachs disease, which can present as a fatal illness of children that causes mental deterioration prior to death, was historically extremely common among Ashkenazi Jews,[19] with lower levels of the disease in some Pennsylvania Dutch, Italian, Irish Catholic, and French Canadian descent, especially those living in the Cajun community of Louisiana and the southeastern Quebec.[20] Since the 1970s, however, proactive genetic testing has been quite effective in eliminating Tay–Sachs from the Ashkenazi Jewish population.[21]
Gaucher's disease, in whichlipids accumulate in inappropriate locations, occurs most frequently among Ashkenazi Jews;[22] the mutation is carried by roughly one in every 15 Ashkenazi Jews, compared to one in 100 of the general American population.[23] Gaucher's disease can causebrain damage andseizures, but these effects are not usually present in the form manifested among Ashkenazi Jews; while those affected still bruise easily, and it can still potentially rupture thespleen, it generally has only a minor impact on life expectancy.
Ashkenazi Jews are also highly affected by otherlysosomal storage diseases, particularly in the form oflipid storage disorders. Compared to other ethnic groups, they more frequently act as carriers ofmucolipidosis[24] andNiemann–Pick disease,[25] the latter of which can prove fatal.
The occurrence of several lysosomal storage disorders in the same population suggests the alleles responsible might have conferred someselective advantage in the past.[26] This would be similar to thehemoglobin allele which is responsible forsickle-cell disease, but solely in people with two copies; those with just one copy of the allele have asickle cell trait and gain partial immunity tomalaria as a result. This effect is calledheterozygote advantage.[27]
Familial dysautonomia (Riley–Day syndrome), which causesvomiting, speech problems, an inability tocry, and falsesensory perception, is almost exclusive to Ashkenazi Jews;[28] Ashkenazi Jews are almost 100 times more likely to carry the disease than anyone else.[29]
Diseases inherited in anautosomal recessive pattern often occur inendogamous populations. Among Ashkenazi Jews, a higher incidence of specificgenetic disorders andhereditarydiseases has been verified, including:
In contrast to the Ashkenazi population,Sephardic andMizrahi Jews are much more divergent groups, with ancestors fromSpain,Portugal,Morocco,Tunisia,Algeria,Italy,Libya,the Balkans,Iran,Kurdistan,Turkey,India, andYemen, with specific genetic disorders found in each regional group, or even in specific subpopulations in these regions.[2]
| Disease | Mode of inheritance | Gene or enzyme | Carrier frequency | Populations | |
|---|---|---|---|---|---|
| Oculocutaneous albinism | Ophthalmology, dermatology | Autosomal recessive | TYR | 1/30 | Morocco |
| Ataxia–telangiectasia | Neurology, medical genetics | Autosomal recessive | ATM | 1/80 | Morocco, Tunisia |
| Creutzfeldt–Jakob disease | Neurology | Autosomal dominant | PRNP | 1/24,000 | Libya |
| Cerebrotendinous xanthomatosis | Medical genetics, endocrinology | Autosomal recessive | CYP27A1 | 1/70 | Morocco |
| Cystinuria | Endocrinology | Autosomal recessive | SLC7A9 | 1/25 | Libya |
| Familial Mediterranean fever | Rheumatology, immunology | Autosomal recessive | MEFV | 1/5–7 | All MENA (Middle Eastern and North African countries). |
| Glycogen storage disease III | Endocrinology | Autosomal recessive | AGL | 1/35 | Morocco, North Africa |
| Limb girdle muscular dystrophy | Neurology | Autosomal recessive | DYSF | 1/10 | Libya |
| Tay–Sachs disease | Neurology | Autosomal recessive | HEXA | 1/110 | Morocco |
| 11-β-hydroxylase deficiency | Endocrinology | Autosomal recessive | CYP11B1 | 1/30–1/128 | Morocco |
| Disease | Mode of inheritance | Gene or enzyme | Carrier frequency | Populations | |
|---|---|---|---|---|---|
| Beta-thalassemia | Hematology | Autosomal recessive | HBB | 1/6 | Iran, Kurdistan, Syria |
| Factor VII deficiency | Hematology, medical genetics | Autosomal recessive | F7 | 1/40 | Iran |
| Familial Mediterranean fever | Rheumatology, immunology | Autosomal recessive, but heterozygous carriers also can show clinical manifestations. | MEFV | 1/5–1/7 | Iran, Kurdistan, Armenia, Azerbaijan, North African Jews, Ashkenazi[49] |
| Glucose-6-phosphate dehydrogenase deficiency | Medical genetics | X-linked | G6PD | 1/4 | Iran, esp. Kurdistan, Syria, and all MENA countries. Female heterozygotes can also show clinical symptoms due to lyonization (X-inactivation), especially during pregnancy.[50] |
| Inclusion body myopathy | Neurology | Autosomal recessive | GNE | 1/12 | Iran |
| Metachromatic leukodystrophy | Endocrinology, neurology | Autosomal recessive | ARSA | 1/50 | Yemen |
| Oculopharyngeal muscular dystrophy | Neurology | Autosomal, recessive or dominant | PABPN1 | 1/7 | Bukhara |
| Phenylketonuria | Medical genetics, pediatrics, dietetics | Autosomal recessive | PAH | 1/35 | Yemen |
One of the firstgenetic testing programs to identifyheterozygote carriers of a genetic disorder was a program aimed at eliminating Tay–Sachs disease. This program began in 1970, and over one million people have now been screened for the mutation.[51] Identifying carriers and counseling couples on reproductive options have had a large impact on the incidence of the disease, with a decrease from 40 to 50 per year worldwide to only four or five per year.[5] Screening programs now test for several genetic disorders in Jews, although these focus on the Ashkenazi Jews, since other Jewish groups cannot be given a single set of tests for a common set of disorders.[3] In the US, these screening programs have been widely accepted by the Ashkenazi community, and have greatly reduced the frequency of the disorders.[52]
Prenatal testing for several genetic diseases is offered as commercial panels for Ashkenazi couples by bothCIGNA andQuest Diagnostics. The CIGNA panel is available for testing for parental/preconception screening or following chorionic villus sampling or amniocentesis and tests for Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia, Gaucher disease, mucolipidosis IV, Neimann-Pick disease type A, Tay-Sachs disease, and torsion dystonia. The Quest panel is for parental/preconception testing and tests for Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Neimann-Pick disease types A and B, and Tay-Sachs disease.
The official recommendation of theAmerican College of Obstetricians and Gynecologists is that Ashkenazi individuals be offered screening for Tay-Sachs disease, Canavan disease, cystic fibrosis, and familial dysautonomia as part of routine obstetrical care.[53]
In theorthodox community, an organization calledDor Yeshorim carries out anonymous genetic screening of couples before marriage to reduce the risk of children with genetic diseases being born.[54] The program educates young people on medical genetics and screens school-aged children for any disease genes. These results are then entered into an anonymous database, identified only by a unique ID number given to the person who was tested. If two people are considering getting married, they call the organization and tell them their ID numbers. The organization then tells them if they are genetically compatible. It is not divulged if one member is a carrier, so as to protect the carrier and his or her family from stigmatization.[54] However, this program has been criticized for exerting social pressure on people to be tested, and for screening for a broad range of recessive genes, including disorders such as Gaucher disease.[4]
Hebrew University ProfessorRaphael Falk published a criticism of studies identifying genetic disorders as being the result of hereditary endogamy.[55]
Dr. Sherry Brandt-Rauf of the University of Illinois and Sheila Rothman of Columbia University co-authored a critique of the methodologies as well as condemning those who worked on the eugenic studies which attributed genetic disorders to religious demographics in paper which explored the ramifications of such concepts entering the workplace stating, "such linkages 'exaggerate genetic differences among ethnic groups' and may result in 'health disparities' in groups not targeted for screening.[56] There has been a tendency to consider Tay-Sachs an exclusively "Jewish" genetic disorder and, as a result of this bias, non-Jewish children with Tay-Sachs may not initially have their disease properly diagnosed and non-Jewish heterozygous carriers may not be aware that they still could carry one of its genetic variants. In a peer-reviewed medical study, a team of researchers from23andMe, one of whom (Noura Abul-Husn) is an Associate Professor of Medicine and Genetics at theIcahn School of Medicine at Mount Sinai, criticized guidelines and policies that restrict Tay-Sachs genetic screening to Jews, French Canadians, and Cajuns.[57] This team found that 59.4 percent of their data pool of 22,681 participants who carry one Tay-Sachs-causing variant on one side of their pair of relevant chromosomes "did not self-report [a] qualifying ethnicity" (one of the three aforementioned populations).[57] They also found that 51.3 percent of participants who carry one Ashkenazi-associated pathogenic variant for 15 different diseases had less than 20 percent Ashkenazi autosomal admixture as calculated by 23andMe. They concluded that restrictive testing "leads to the under-detection of heterozygotes and associated reproductive risk" of having a child with a serious disease.[57]
Type III is familial dysautonomia or Riley–Day syndrome. It is multisystemic and affects mainly Ashkenazi Jews.
We have previously linked families with autosomal-dominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8)...
A son and daughter of consanguineous Ashkenazi Jewish parents presented with phenotypic features that are typically seen in Zellweger syndrome...
